Changes in CD4+ T lymphocyte subsets in circulating blood and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis
- PMID: 10341394
- DOI: 10.1046/j.1526-0968.1999.00136.x
Changes in CD4+ T lymphocyte subsets in circulating blood and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis
Abstract
The purpose of this study is to determine the changes in CD4+ T lymphocyte subsets in the circulating blood and synovial fluid following filtration leukocytapheresis (LCP) therapy for patients with rheumatoid arthritis (RA). A Cellsorba column packed with polyester fibers was used for the removal of circulating leukocytes. For patients with RA, filtration LCP or sham procedures were performed 3 times with 1 week intervals between procedures. T lymphocyte surface markers in the peripheral blood and synovial fluid were measured by flow cytometry. The proportions of activated CD4+ T cells (CD4+DR+, CD4+CD25+, and CD4+CD71+) and CD4+CD29+ T cells increased significantly in the peripheral blood, but the counts of these cells were significantly reduced in the synovial fluid after 2 treatment sessions in the LCP group. No significant changes were observed in the proportion of these cells in the control group. Our findings suggest that filtration LCP may cause a redistribution of activated T cells from affected joints into the circulating blood.
Similar articles
-
The mechanism of the efficiency of leukocytapheresis on rheumatoid arthritis.Ther Apher. 1997 Aug;1(3):215-8. doi: 10.1111/j.1744-9987.1997.tb00140.x. Ther Apher. 1997. PMID: 10225741
-
Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis.J Clin Apher. 2001;16(2):74-81. doi: 10.1002/jca.1016. J Clin Apher. 2001. PMID: 11746532 Clinical Trial.
-
Comparison of lymphocyte depletion and clinical effectiveness on filtration leukocytapheresis in patients with rheumatoid arthritis.Ther Apher. 2001 Dec;5(6):455-61. doi: 10.1046/j.1526-0968.2001.00375.x. Ther Apher. 2001. PMID: 11800080
-
[The mechanism of the efficiency of leukocytapheresis on rheumatoid arthritis].Nihon Rinsho Meneki Gakkai Kaishi. 2011;34(6):447-55. doi: 10.2177/jsci.34.447. Nihon Rinsho Meneki Gakkai Kaishi. 2011. PMID: 22214805 Review. Japanese.
-
[Leukocytapheresis for therapy of rheumatoid arthritis].Nihon Rinsho. 2005 Jan;63 Suppl 1:649-52. Nihon Rinsho. 2005. PMID: 15799436 Review. Japanese. No abstract available.
Cited by
-
The type of responder T-cell has a significant impact in a human in vitro suppression assay.PLoS One. 2010 Dec 3;5(12):e15154. doi: 10.1371/journal.pone.0015154. PLoS One. 2010. PMID: 21151941 Free PMC article.
-
Role of apheresis in rheumatoid arthritis.Drugs. 2006;66(15):1903-8. doi: 10.2165/00003495-200666150-00001. Drugs. 2006. PMID: 17100402 Review.
-
TOAST: improving reference-free cell composition estimation by cross-cell type differential analysis.Genome Biol. 2019 Sep 4;20(1):190. doi: 10.1186/s13059-019-1778-0. Genome Biol. 2019. PMID: 31484546 Free PMC article.
-
Current topics on therapeutic apheresis.J Artif Organs. 2010 Jul;13(2):73-6. doi: 10.1007/s10047-010-0501-4. Epub 2010 Apr 3. J Artif Organs. 2010. PMID: 20364285 Review.
-
Modulation of platelet aggregation responses by leukocytapheresis therapy in patients with active ulcerative colitis.J Gastroenterol. 2006 Jun;41(6):540-6. doi: 10.1007/s00535-006-1797-y. J Gastroenterol. 2006. PMID: 16868801
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials